NCT00954278 is a Phase 1 clinical trial of sorafenib in Carcinoma, Non Small Cell Lung, sponsored by University of Wisconsin, Madison.

Who is sponsoring NCT00954278?

NCT00954278 is sponsored by University of Wisconsin, Madison.

What drugs are being tested in NCT00954278?

Interventions in NCT00954278: sorafenib.

What condition does NCT00954278 study?

NCT00954278 studies Carcinoma, Non Small Cell Lung.

Is NCT00954278 still recruiting?

NCT00954278 is currently completed. Last updated 15 November 2019.

Last reviewed 2019-11-15 · How we verify

NCT00954278

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer

Completed Phase 1 Last updated 15 November 2019

What this trial tests

Phase 1 trial testing sorafenib in Carcinoma, Non Small Cell Lung in 24 participants. Completed in 23 December 2015.

Timeline

28 July 2009

Primary endpoint
23 December 2015

23 December 2015

Quick facts

Lead sponsor	University of Wisconsin, Madison
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	28 July 2009
Primary completion	23 December 2015
Estimated completion	23 December 2015
Sites	1 location across United States

Drugs / interventions tested

sorafenib (SORAFENIB) — full drug profile →

Conditions studied

Carcinoma, Non Small Cell Lung — all drugs for Carcinoma, Non Small Cell Lung →

Sponsor

University of Wisconsin, Madison

Who can join

18 and older, any sex, with Carcinoma, Non Small Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the number of patients with advanced, relapsed non-small cell lung cancer who can tolerate dose escalation sorafenib from 400 mg twice daily to either 600 mg twice daily or 800 mg twice daily. Safety and tolerability of sorafenib will also be examined.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience.
Semrad TJ, Gandara DR, Lara PN. · · 2011 · cited 10× · PMID 21789159 · DOI 10.1177/1758834010396117

Verify or expand the search:

Other trials of sorafenib

Trials testing the same drug.

NCT02425605 — Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Car · Phase 2 · completed
NCT02143726 — Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle · Phase 2 · active not recruiting
NCT01434602 — Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas · Phase 1, PHASE2 · completed
NCT01357486 — Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis · Phase 2 · completed
NCT00627835 — Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squ · Phase 1 · withdrawn

Other recruiting trials for Carcinoma, Non Small Cell Lung

Currently open trials in the same condition.

NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
NCT06974734 — A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies · Phase 1 · active not recruiting

Other University of Wisconsin, Madison trials

Trials by the same sponsor.

NCT07440004 — Testing a Digital Mindfulness Program to Support People Experiencing Suicidal Thoughts · Phase 1 · recruiting
NCT07278466 — The COMParing App Support Strategies Study · NA · recruiting
NCT07475104 — Redesigning Surgical Care for Patients in Wisconsin · NA · enrolling by invitation
NCT07470723 — The ORIGIN-FH Study · NA · recruiting
NCT06975657 — Well-being Skills for Reentry · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00954278 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Wisconsin, Madison
Last refreshed: 15 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00954278.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing